Endocrinol Metab.  2021 Feb;36(1):81-95. 10.3803/EnM.2020.833.

Efficacy of Ethanol Ablation for Benign Thyroid Cysts and Predominantly Cystic Nodules: A Systematic Review and Meta-Analysis

Affiliations
  • 1Department of Medical Imaging, Chi Mei Medical Center, Tainan, Taiwan

Abstract

Background
Ultrasound-guided minimally invasive procedures are widely used to treat thyroid diseases. The objective of this study was to assess the efficacy and safety of ethanol ablation (EA) in comparison with other non-surgical options in the treatment of benign thyroid cystic nodules.
Methods
We conducted a systematic search of studies on EA for thyroid cystic nodules, mainly in the Ovid-MEDLINE and Embase, Web of Science, and Cochrane databases. The standardized mean difference (SMD) of the volume reduction ratio (VRR) after EA versus other non-surgical treatments comprised the primary outcome, whereas the odds ratio (OR) of therapeutic success rates between the two groups comprised the secondary outcome.
Results
The meta-analysis included 19 studies (four randomized controlled trials and 15 non-randomized studies) with 1,514 participants. The cumulative VRR of EA was 83.908% (95% confidence interval [CI], 79.358% to 88.457%). EA had a significantly higher pooled VRR (SMD, 0.381; 95% CI, 0.028 to 0.734; P=0.030), but not a significantly higher pooled therapeutic success rate (OR, 0.867; 95% CI, 0.132 to 5.689; P=0.880), than other forms of non-surgical management including radiofrequency ablation (RFA), polidocanol sclerotherapy, and simple aspiration with or without saline flush. However, the VRR and therapeutic success rate were not significantly different between EA and RFA. Major complications were recorded only in six patients (0.53%) with self-limiting dysphonia.
Conclusion
The role of EA as the first-line treatment for benign thyroid cysts and predominantly cystic nodules is supported by its high effectiveness and good safety profile compared to other currently available non-surgical options.

Keyword

Ethanol; Ablation techniques; Sclerotherapy; Thyroid nodule; Cyst; Meta-analysis

Figure

  • Fig. 1 Flow diagram summarizing the literature review process according to the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) guideline. VRR, volume reduction ratio; EA, ethanol ablation.

  • Fig. 2 Summary of quality assessment of the included randomized controlled trials according to Risk-of-Bias tool 2.0 (RoB 2.0) (A), and non-randomized studies according to Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS) (B).

  • Fig. 3 Forest plots summarizing the efficacy of ethanol ablation (EA) in treating cystic thyroid nodules measured by the volume reduction ratio as compared with other types of non-surgical management, overall effects, and subgroup analysis according to different comparators (A) and cysts versus predominantly cystic thyroid nodules (PCTNs) (B). SD, standard deviation; IV, inverse variance method; CI, confidence interval; RFA, radiofrequency ablation.

  • Fig. 4 Forest plots summarizing the therapeutic success rate of ethanol ablation (EA) as compared with other types of non-surgical management, overall effects, and subgroup analysis according to different comparators (A) and cysts versus predominantly cystic thyroid nodules (PCTNs) (B). M-H, Mantel-Haenszel; CI, confidence interval; RFA, radiofrequency ablation.

  • Fig. 5 Funnel plots of studies that evaluated the volume reduction ratio. SE, standard error; SMD, standardized mean difference; EA, ethanol ablation; RFA, radiofrequency ablation.


Reference

1. Russ G, Leboulleux S, Leenhardt L, Hegedus L. Thyroid incidentalomas: epidemiology, risk stratification with ultrasound and workup. Eur Thyroid J. 2014; 3:154–63.
Article
2. Rojeski MT, Gharib H. Nodular thyroid disease. Evaluation and management. N Engl J Med. 1985; 313:428–36.
3. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The diagnosis and management of thyroid nodules: a review. JAMA. 2018; 319:914–24.
4. Smith MD, Serpell JW, Morgan JL, Cheng MS. Fine needle aspiration in the management of benign thyroid cysts. ANZ J Surg. 2003; 73:477–9.
Article
5. Choi WJ, Baek JH, Choi YJ, Lee JH, Ha EJ, Lee WC, et al. Management of cystic or predominantly cystic thyroid nodules: role of simple aspiration of internal fluid. Endocr Res. 2015; 40:215–9.
Article
6. Ferreira MC, Piaia C, Cadore AC. Percutaneous ethanol injection versus conservative treatment for benign cystic and mixed thyroid nodules. Arch Endocrinol Metab. 2016; 60:211–6.
Article
7. Zingrillo M, Torlontano M, Chiarella R, Ghiggi MR, Nirchio V, Bisceglia M, et al. Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid. 1999; 9:763–7.
Article
8. Sung JY, Kim YS, Choi H, Lee JH, Baek JH. Optimum first-line treatment technique for benign cystic thyroid nodules: ethanol ablation or radiofrequency ablation? AJR Am J Roentgenol. 2011; 196:W210–4.
Article
9. Gong X, Wang F, Du H, Chen X, Shi B. Comparison of ultrasound-guided percutaneous polidocanol injection versus percutaneous ethanol injection for treatment of benign cystic thyroid nodules. J Ultrasound Med. 2018; 37:1423–9.
Article
10. Sung JY, Baek JH, Kim KS, Lee D, Yoo H, Kim JK, et al. Single-session treatment of benign cystic thyroid nodules with ethanol versus radiofrequency ablation: a prospective randomized study. Radiology. 2013; 269:293–300.
Article
11. Bennedbaek FN, Hegedus L. Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab. 2003; 88:5773–7.
Article
12. Kim JH, Lee HK, Lee JH, Ahn IM, Choi CG. Efficacy of sonographically guided percutaneous ethanol injection for treatment of thyroid cysts versus solid thyroid nodules. AJR Am J Roentgenol. 2003; 180:1723–6.
Article
13. Baek JH, Ha EJ, Choi YJ, Sung JY, Kim JK, Shong YK. Radiofrequency versus ethanol ablation for treating predominantly cystic thyroid nodules: a randomized clinical trial. Korean J Radiol. 2015; 16:1332–40.
Article
14. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: 2016 update. Endocr Pract. 2016; 22:622–39.
15. Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer. 1991; 68:1524–30.
Article
16. Albanese G, Kondo KL. Pharmacology of sclerotherapy. Semin Intervent Radiol. 2010; 27:391–9.
Article
17. Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011; 258:351–69.
Article
18. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26:1–133.
Article
19. Papini E, Monpeyssen H, Frasoldati A, Hegedus L. 2020 European Thyroid Association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules. Eur Thyroid J. 2020; 9:172–85.
Article
20. Feldkamp J, Grunwald F, Luster M, Lorenz K, Vorlander C, Fuhrer D. Non-surgical and non-radioiodine techniques for ablation of benign thyroid nodules: consensus statement and recommendation. Exp Clin Endocrinol Diabetes. 2020; 128:687–92.
Article
21. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2017 Thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J Radiol. 2018; 19:632–55.
Article
22. Hahn SY, Shin JH, Na DG, Ha EJ, Ahn HS, Lim HK, et al. Ethanol ablation of the thyroid nodules: 2018 consensus statement by the Korean Society of Thyroid Radiology. Korean J Radiol. 2019; 20:609–20.
Article
23. Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol. 2008; 18:1244–50.
Article
24. Lim HK, Lee JH, Ha EJ, Sung JY, Kim JK, Baek JH. Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. Eur Radiol. 2013; 23:1044–9.
Article
25. Aysan E, Idiz UO, Akbulut H, Elmas L. Single-session radiofrequency ablation on benign thyroid nodules: a prospective single center study : radiofrequency ablation on thyroid. Langenbecks Arch Surg. 2016; 401:357–63.
Article
26. Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid. 2006; 16:361–7.
Article
27. Khalilzadeh O, Baerlocher MO, Shyn PB, Connolly BL, Devane AM, Morris CS, et al. Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol. 2017; 28:1432–7.
Article
28. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898.
Article
29. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013; 66:408–14.
Article
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–60.
Article
31. Valcavi R, Frasoldati A. Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules. Endocr Pract. 2004; 10:269–75.
Article
32. Verde G, Papini E, Pacella CM, Gallotti C, Delpiano S, Strada S, et al. Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules. Clin Endocrinol (Oxf). 1994; 41:719–24.
Article
33. Cho YS, Lee HK, Ahn IM, Lim SM, Kim DH, Choi CG, et al. Sonographically guided ethanol sclerotherapy for benign thyroid cysts: results in 22 patients. AJR Am J Roentgenol. 2000; 174:213–6.
34. Guglielmi R, Pacella CM, Bianchini A, Bizzarri G, Rinaldi R, Graziano FM, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid. 2004; 14:125–31.
Article
35. Jang SW, Baek JH, Kim JK, Sung JY, Choi H, Lim HK, et al. How to manage the patients with unsatisfactory results after ethanol ablation for thyroid nodules: role of radiofrequency ablation. Eur J Radiol. 2012; 81:905–10.
Article
36. Perez CL, Fighera TM, Miasaki F, Mesa Junior CO, Paz Filho GJ, Graf H, et al. Evaluation of percutaneous ethanol injections in benign thyroid nodules. Arq Bras Endocrinol Metabol. 2014; 58:912–7.
Article
37. Negro R, Colosimo E, Greco G. Outcome, pain perception, and health-related quality of life in patients submitted to percutaneous ethanol injection for simple thyroid cysts. J Thyroid Res. 2017; 2017:9536479.
Article
38. Espenbetova M, Amrenova K, Zhumanbayeva Z, Zamanbekova Z, Yurkovskaya O, Shalgumbayeva G, et al. Effectiveness of percutaneous ethanol injection in nodular diseases of the thyroid gland: 10-year follow-up. Endoc Pract. 2018; 24:982–7.
Article
39. Ozderya A, Aydin K, Gokkaya N, Temizkan S. Percutaneous ethanol injection for benign cystic and mixed thyroid nodules. Endocr Pract. 2018; 24:548–55.
Article
40. Halenka M, Karasek D, Schovanek J, Frysak Z. Safe and effective percutaneous ethanol injection therapy of 200 thyroid cysts. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020; 164:161–7.
Article
41. Reverter JL, Alonso N, Avila M, Lucas A, Mauricio D, Puig-Domingo M. Evaluation of efficacy, safety, pain perception and health-related quality of life of percutaneous ethanol injection as first-line treatment in symptomatic thyroid cysts. BMC Endocr Disord. 2015; 15:73.
Article
42. Park HS, Yim Y, Baek JH, Choi YJ, Shong YK, Lee JH. Ethanol ablation as a treatment strategy for benign cystic thyroid nodules: a comparison of the ethanol retention and aspiration techniques. Ultrasonography. 2019; 38:166–71.
Article
43. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007; 7:5.
Article
44. Lee GM, You JY, Kim HY, Chai YJ, Kim HK, Dionigi G, et al. Successful radiofrequency ablation strategies for benign thyroid nodules. Endocrine. 2019; 64:316–21.
Article
45. Kim YJ, Baek JH, Ha EJ, Lim HK, Lee JH, Sung JY, et al. Cystic versus predominantly cystic thyroid nodules: efficacy of ethanol ablation and analysis of related factors. Eur Radiol. 2012; 22:1573–8.
Article
46. Hegedus L, Hansen JM, Karstrup S, Torp-Pedersen S, Juul N. Tetracycline for sclerosis of thyroid cysts. A randomized study. Arch Intern Med. 1988; 148:1116–8.
Article
47. Kalra N, Ahuja CK, Dutta P, Rajwanshi A, Mittal BR, Bhansali A, et al. Comparison of sonographically guided percutaneous sodium tetradecyl sulfate injection with ethanol injection in the treatment of benign nonfunctioning thyroid nodules. J Vasc Interv Radiol. 2014; 25:1218–24.
Article
48. Dong Y, Zhou J, Liu Z, Luo T, Zhan W. Efficacy assessment of ultrasound guided lauromacrogol injection for ablation of benign cystic and predominantly cystic thyroid nodules. Front Pharmacol. 2019; 10:478.
Article
49. Yuce G, Ates OF, Polat B, Genc B, Canyigit M. Ablation of cystic thyroid nodules with n-butyl cyanoacrylate: a preliminary study. Endocr Pract. 2020; 26:492–8.
Article
50. In HS, Kim DW, Choo HJ, Jung SJ, Kang T, Ryu JH. Ethanol ablation of benign thyroid cysts and predominantly cystic thyroid nodules: factors that predict outcome. Endocrine. 2014; 46:107–13.
Article
51. Suh CH, Baek JH, Ha EJ, Choi YJ, Lee JH, Kim JK, et al. Ethanol ablation of predominantly cystic thyroid nodules: evaluation of recurrence rate and factors related to recurrence. Clin Radiol. 2015; 70:42–7.
Article
52. Kim DW, Rho MH, Kim HJ, Kwon JS, Sung YS, Lee SW. Percutaneous ethanol injection for benign cystic thyroid nodules: is aspiration of ethanol-mixed fluid advantageous? AJNR Am J Neuroradiol. 2005; 26:2122–7.
53. Lee SJ, Ahn IM. Effectiveness of percutaneous ethanol injection therapy in benign nodular and cystic thyroid diseases: long-term follow-up experience. Endocr J. 2005; 52:455–62.
Article
54. Solymosi T. Percutaneous ethanol injection efficacy in the treatment of benign thyroid nodules. Ten-year follow-up of 254 patients. Orv Hetil. 2020; 161:224–31.
55. Monzani F, Lippi F, Goletti O, Del Guerra P, Caraccio N, Lippolis PV, et al. Percutaneous aspiration and ethanol sclerotherapy for thyroid cysts. J Clin Endocrinol Metab. 1994; 78:800–2.
Article
56. Lee JH, Kim YS, Lee D, Choi H, Yoo H, Baek JH. Radiofrequency ablation (RFA) of benign thyroid nodules in patients with incompletely resolved clinical problems after ethanol ablation (EA). World J Surg. 2010; 34:1488–93.
Article
57. Kim DW. Sonography-guided ethanol ablation of a remnant solid component after radio-frequency ablation of benign solid thyroid nodules: a preliminary study. AJNR Am J Neuroradiol. 2012; 33:1139–43.
Article
58. Park HS, Baek JH, Choi YJ, Lee JH. Innovative techniques for image-guided ablation of benign thyroid nodules: combined ethanol and radiofrequency ablation. Korean J Radiol. 2017; 18:461–9.
Article
59. Baek JH, Lee JH, Sung JY, Bae JI, Kim KT, Sim J, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. Radiology. 2012; 262:335–42.
Article
60. Mauz PS, Maassen MM, Braun B, Brosch S. How safe is percutaneous ethanol injection for treatment of thyroid nodule? Report of a case of severe toxic necrosis of the larynx and adjacent skin. Acta Otolaryngol. 2004; 124:1226–30.
Article
61. Park NH, Kim DW, Park HJ, Lee EJ, Park JS, Park SI, et al. Thyroid cysts treated with ethanol ablation can mimic malignancy during sonographic follow-up. J Clin Ultrasound. 2011; 39:441–6.
Article
62. Park JS, Kim DW, Eun CK, Choi SJ, Rho MH. Long-term follow-up sonography of benign cystic thyroid nodules after a percutaneous ethanol injection: the incidence of malignancy-mimicking nodules. J Korean Radiol Soc. 2008; 58:21–8.
Article
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr